These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. A Pilot Study of Checkpoint Inhibitors in Solid Organ Transplant Recipients with Metastatic Cutaneous Squamous Cell Carcinoma. Tsung I; Worden FP; Fontana RJ Oncologist; 2021 Feb; 26(2):133-138. PubMed ID: 32969143 [TBL] [Abstract][Full Text] [Related]
10. Immune checkpoint blockade with anti-programmed cell death 1 (PD-1) monoclonal antibody (mAb) cemiplimab: ongoing and future perspectives in rare genital cancers treatment. Gambale E; Fancelli S; Caliman E; Petrella MC; Doni L; Pillozzi S; Antonuzzo L J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35101944 [TBL] [Abstract][Full Text] [Related]
11. Real-Life Study of the Benefit of Concomitant Radiotherapy with Cemiplimab in Advanced Cutaneous Squamous Cell Carcinoma (cSCC): A Retrospective Cohort Study. Bailly-Caillé B; Kottler D; Morello R; Lecornu M; Kao W; Meyer E; Dompmartin A; L'Orphelin JM Cancers (Basel); 2023 Jan; 15(2):. PubMed ID: 36672444 [TBL] [Abstract][Full Text] [Related]
12. Immune landscape and immunotherapy for penile cancer. Tang Y; Hu X; Wu K; Li X Front Immunol; 2022; 13():1055235. PubMed ID: 36524123 [TBL] [Abstract][Full Text] [Related]
13. PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma. Migden MR; Rischin D; Schmults CD; Guminski A; Hauschild A; Lewis KD; Chung CH; Hernandez-Aya L; Lim AM; Chang ALS; Rabinowits G; Thai AA; Dunn LA; Hughes BGM; Khushalani NI; Modi B; Schadendorf D; Gao B; Seebach F; Li S; Li J; Mathias M; Booth J; Mohan K; Stankevich E; Babiker HM; Brana I; Gil-Martin M; Homsi J; Johnson ML; Moreno V; Niu J; Owonikoko TK; Papadopoulos KP; Yancopoulos GD; Lowy I; Fury MG N Engl J Med; 2018 Jul; 379(4):341-351. PubMed ID: 29863979 [TBL] [Abstract][Full Text] [Related]
14. Supraorbital Basosquamous Carcinoma Treated with Cemiplimab Followed by Sonidegib: A Case Report and Review of the Literature. Proietti I; Filippi L; Tolino E; Bernardini N; Svara F; Trovato F; Di Cristofano C; Petrozza V; Bagni O; Vizzaccaro A; Skroza N; Potenza C Biomedicines; 2023 Oct; 11(11):. PubMed ID: 38001904 [No Abstract] [Full Text] [Related]
15. Cemiplimab for advanced cutaneous squamous cell carcinoma in kidney transplant recipients. Van Meerhaeghe T; Baurain JF; Bechter O; Orte Cano C; Del Marmol V; Devresse A; Doubel P; Hanssens M; Hellemans R; Lienard D; Rutten A; Sprangers B; Le Moine A; Aspeslagh S Front Nephrol; 2022; 2():1041819. PubMed ID: 37675002 [TBL] [Abstract][Full Text] [Related]
16. Case Report: Autoimmune Pemphigus Vulgaris in a Patient Treated With Cemiplimab for Multiple Locally Advanced Cutaneous Squamous Cell Carcinoma. Buquicchio R; Mastrandrea V; Strippoli S; Quaresmini D; Guida M; Filotico R Front Oncol; 2021; 11():691980. PubMed ID: 34540666 [TBL] [Abstract][Full Text] [Related]
17. Promising Immune Treatment of Advanced Cutaneous Squamous Cell Carcinoma with Cemiplimab-Real-World Experience in the Global SARS-CoV-2 Pandemic. Pabianek M; Lesiak A; Nejc D; Kuncman Ł; Narbutt J; Skibińska M; Ciążyńska M Curr Oncol; 2022 Oct; 29(10):7794-7801. PubMed ID: 36290893 [TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of maintenance immune checkpoint inhibitors with or without pemetrexed in advanced non-squamous non-small cell lung cancer: a retrospective study. Gu X; Shi Z; Shao L; Zhang Y; Zhang Y; Song Z; Wang W; Lou G BMC Cancer; 2022 May; 22(1):576. PubMed ID: 35606756 [TBL] [Abstract][Full Text] [Related]
19. Cemiplimab in an Elderly Frail Population of Patients With Locally Advanced or Metastatic Cutaneous Squamous Cell Carcinoma: A Single-Center Real-Life Experience From Italy. Strippoli S; Fanizzi A; Quaresmini D; Nardone A; Armenio A; Figliuolo F; Filotico R; Fucci L; Mele F; Traversa M; De Luca F; Montagna ES; Ruggieri E; Ferraiuolo S; Macina F; Tommasi S; Sciacovelli AM; De Risi I; Albano A; Massafra R; Guida M Front Oncol; 2021; 11():686308. PubMed ID: 34820323 [TBL] [Abstract][Full Text] [Related]
20. Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial. Sezer A; Kilickap S; Gümüş M; Bondarenko I; Özgüroğlu M; Gogishvili M; Turk HM; Cicin I; Bentsion D; Gladkov O; Clingan P; Sriuranpong V; Rizvi N; Gao B; Li S; Lee S; McGuire K; Chen CI; Makharadze T; Paydas S; Nechaeva M; Seebach F; Weinreich DM; Yancopoulos GD; Gullo G; Lowy I; Rietschel P Lancet; 2021 Feb; 397(10274):592-604. PubMed ID: 33581821 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]